Triastek Inc. has concluded its First-in-Human (FIH) study of its new 3D printing drug, T21. This drug is designed to treat moderate to severe ulcerative colitis (UC).
According to the study’s imaging findings, T21 tablets demonstrate accurate delivery and controlled release to the colon, where the drug is intended to take effect. The tablets are produced using the company’s Melt Extrusion Deposition 3D printing process, which allows for precise regulation of the drug’s release in the gastrointestinal tract. As a result, this technology ensures a more focused and effective drug delivery mechanism.
Read more about it here.